Taurultam (CAS 38668-01-8)
QUICK LINKS
Taurultam, a synthetic analogue of the neurotransmitter taurine, has been utilized in various laboratory experiments since its introduction in the early 2000s. In scientific studies, taurultam has been employed to explore taurine′s influence on the central nervous system and its potential impact on neurological health. Research has also extended to its effects on cardiovascular health and immune system responses. The compound is thought to primarily function as an agonist at glycine receptors, which are inhibitory neurotransmitter receptors in the brain and spinal cord, by enhancing the receptor activity and thereby exerting a calming effect on neural activity. Furthermore, taurultam is associated with increased brain taurine levels, which is believed to contribute to its experimental outcomes.
Taurultam (CAS 38668-01-8) References
- Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. | Calabresi, P., et al. 2001. Cancer Res. 61: 6816-21. PMID: 11559556
- The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. | Braumann, C., et al. 2004. Int J Cancer. 112: 225-30. PMID: 15352034
- Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. | Jacobi, CA., et al. 2005. Anticancer Drugs. 16: 917-21. PMID: 16162968
- Studies of the thiadiazine, taurolidine-I. Identification of the molecular species present in aqueous solutions by (1)H- and (13)C-NMR spectroscopy. | Hood, HT., et al. 1994. Talanta. 41: 107-13. PMID: 18965894
- [The protoskolicidal effect of 1% polyvinylpyrrolidone-iodine (PVP-1) and 2% taurolidine on abdominal hydatidosis]. | Ekçı, B., et al. 2010. Turkiye Parazitol Derg. 34: 152-5. PMID: 20954114
- Taurolidine and congeners activate hTRPA1 but not hTRPV1 channels and stimulate CGRP release from mouse tracheal sensory nerves. | Kichko, TI., et al. 2016. Pharmacol Res Perspect. 4: e00204. PMID: 26977296
- Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. | Buchholz, M., et al. 2017. BMC Cancer. 17: 216. PMID: 28340556
- Antifungal activity of Taurolidine against Mucorales: An in vitro study on clinical isolates. | Jafarian, H., et al. 2022. Curr Med Mycol. 8: 26-31. PMID: 36340433
- Quantitation of taurolidine decomposition in polymer solutions by chromotropic acid formaldehyde assay method. | Sihn, YS., et al. 1997. J Pharm Biomed Anal. 16: 643-50. PMID: 9502160
- The effect of polyvinylpyrrolidine on the stability of taurolidine. | Kirsch, LE. and Sihn, YS. 1997. Pharm Dev Technol. 2: 345-56. PMID: 9552463
- Polarographic analysis of taurolidine, a non-antibiotic antimicrobial agent | Woolfson, A. D., McCafferty, D. F., Gorman, S. P., & Jones, D. S. 1988. International journal of pharmaceutics. 48(1-3): 167-172.
- Assay procedures for Taurolin solutions using pre-column derivatisation and high-performance liquid chromatography with fluorescence detection | Woolfson, A. D., Gorman, S. P., McCafferty, D. F., & Jones, D. S. 1989. International journal of pharmaceutics. 49(2): 135-140.
- Comparison of the growth inhibitory and bacteriocidal effects of taurolidine and taurultam on a clinical isolate of Escherichia coli | Jones, D. S., Gorman, S. P., McCafferty, D. F., & Woolfson, A. D. 1992. Letters in applied microbiology. 14(1): 5-9.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Taurultam, 10 mg | sc-475052 | 10 mg | $321.00 | |||
Taurultam, 100 mg | sc-475052A | 100 mg | $2958.00 |